Future Opportunities in Genitourinary Cancers

EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers

EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023

EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape

EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer

EP: 5.Key Highlights from EV-302 Study at ESMO 2023

EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023

Now Viewing

EP: 7.Future Opportunities in Genitourinary Cancers

This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.

Daneshmand discusses areas for improving genitourinary cancer management. Better biomarkers are needed to guide personalized therapy rather than one-size-fits-all approaches. Although genomic profiling has expanded, adequate predictive and response biomarkers are still lacking beyond select cases like FGFR3-altered bladder cancer.

Circulating tumor DNA (ctDNA) analysis is an exciting area, as seen in other cancers, to detect molecular disease and help guide adjuvant treatment decisions. Ongoing trials are evaluating ctDNA’s role in locally advanced bladder cancer.

Daneshmand briefly highlights 2 other promising European Society for Medical Oncology Congress 2023 abstracts: one on gemcitabine, cisplatin, and nivolumab in urothelial carcinoma; and TAR-210, using an intravesical formulation of erdafitinib across bladder cancer settings.

In conclusion, Daneshmand notes he is excited about the future, with these innovative trials prolonging patient survival. He sees expanded treatment options allowing patients with bladder cancer to avoid dramatic interventions like cystectomy. But continued work is needed.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.